EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark SYNTHORX was filed as Word mark on 02/15/2019 at the European Union Intellectual Property Office.
It was registered as a trademark on 07/20/2019.
The current status of the mark is "Trademark registered".
| Trademark form | Word mark |
| File reference | 018023677 |
| Application date | February 15, 2019 |
| Publication date | April 12, 2019 |
| Entry date | July 20, 2019 |
| Expiration date | February 15, 2029 |
Trademark owner
11099 N. Torrey Pines Road, Suite 190
92037 La Jolla
US
92037 La Jolla
US
Trademark representatives
Arne Jacobsens Allé 15
2300 Copenhagen S
DK
goods and services
5
Protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases, and infectious diseases; protein therapeutics expressed, prepared or manufactured using a semisynthetic organism, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases; protein therapeutics namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, coagulation factors, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, anti-infectives, pain killers, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics; pharmaceutical, medical and therapeutic preparations for treating illness
42
Medical research; scientific research in the field of DNA; pharmaceutical research and development; laboratory research services in the field of pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, geriatrics, genetics and phenomics, pathology and forensics, proteomics, and veterinary medicine and diagnostics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| September 3, 2024 | Change Representative, Published | ||
| June 17, 2021 | Transfer / Change of address, Published | ||
| December 10, 2019 | Change Representative, Published | ||
| November 22, 2019 | Change Representative, Published |
ID: 11018023677